← All trials
NCT05814406
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 12, 2023
- Primary completion
- Jun 15, 2025
- Completion date
- Dec 15, 2025
- First posted
- Apr 14, 2023
- Last posted
- May 6, 2023
- Enrollment
- 180
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- JW PharmaceuticalLead sponsor
- Chosun UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.